{"entity":{"id":"nct07460375","kind":"trial","name":"A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of LCB02A in advanced solid tumours, run by LigaChem Biosciences, Inc., now recruiting.","summary":"A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07460375 by LigaChem Biosciences, Inc., with 191 participants planned, started 2026-08 and due to reach its primary completion in 2030-02. Interventions recorded: LCB02A.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07460375","url":"https://clinicaltrials.gov/study/NCT07460375"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["lcb02a"],"companies":["ligachem-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07460375","phase":"1/2","setting":"A First-in-Human Phase 1/2, Dose Escalation and Dose Expansion Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of Claudin18.2 (CLDN18.2)-Directed Antibody-Drug Conjugate (ADC) LCB02A in Patients With CLDN18.2-positive Advanced Solid Tumors","sponsor":"LigaChem Biosciences, Inc.","enrolled":191,"outcomes":[]},"route":"/trials/nct07460375/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"lcb02a","kind":"drug","name":"LCB02A","route":"/drugs/lcb02a/"}],"company":[{"id":"ligachem-biosciences","kind":"company","name":"LigaChem Biosciences","route":"/companies/ligachem-biosciences/"}]}}